Anke Biotech announced that the company has received the “Notice of Acceptance”, an administrative licensing document from the State Drug Administration, and the application for registration and marketing license for injectable cetrorelix acetate has been accepted. This drug is a third-generation gonadotropin-releasing hormone antagonist. It is indicated to prevent premature ovulation in assisted fertility techniques, and has the advantages of rapid efficacy and low incidence of ovarian hyperstimulation syndrome and adverse events. This acceptance is only a phased result of the development of a new drug, and there is still uncertainty about whether it will be approved for marketing in the future.

Anke Biotech announced that the company has received the “Notice of Acceptance”, an administrative licensing document from the State Drug Administration, and the application for registration and marketing license for injectable cetrorelix acetate has been accepted. This drug is a third-generation gonadotropin-releasing hormone antagonist. It is indicated to prevent premature ovulation in assisted fertility techniques, and has the advantages of rapid efficacy and low incidence of ovarian hyperstimulation syndrome and adverse events. This acceptance is only a phased result of the development of a new drug, and there is still uncertainty about whether it will be approved for marketing in the future.